Stimulation of β-adrenoceptors Up-regulates Cardiac Expression of Galectin-3 and BIM Through the Hippo Signalling Pathway
Overview
Authors
Affiliations
Background And Purpose: Expression of the pro-fibrotic galectin-3 and the pro-apoptotic BIM is elevated in diseased heart or after β-adrenoceptor stimulation, but the underlying mechanisms are unclear. This question was addressed in the present study.
Experimental Approach: Wild-type mice and mice with cardiac transgenic expression of β -adrenoceptors, mammalian sterile-20 like kinase 1 (Mst1) or dominant-negative Mst1, and non-specific galectin-3 knockout mice were used. Effects of the β-adrenoceptor agonist isoprenaline or β-adrenoceptor antagonists were studied. Rat cardiomyoblasts (H9c2) were used for mechanistic exploration. Biochemical assays were performed.
Key Results: Isoprenaline treatment up-regulated expression of galectin-3 and BIM, and this was inhibited by non-selective or selective β-adrenoceptor antagonists (by 60-70%). Cardiac expression of galectin-3 and BIM was increased in β -adrenoceptor transgenic mice. Isoprenaline-induced up-regulation of galectin-3 and BIM was attenuated by Mst1 inactivation, but isoprenaline-induced galectin-3 expression was exaggerated by transgenic Mst1 activation. Pharmacological or genetic activation of β-adrenoceptors induced Mst1 expression and yes-associated protein (YAP) phosphorylation. YAP hyper-phosphorylation was also evident in Mst1 transgenic hearts with up-regulated expression of galectin-3 (40-fold) and BIM as well as up-regulation of many YAP-target genes by RNA sequencing. In H9c2 cells, isoprenaline induced YAP phosphorylation and expression of galectin-3 and BIM, effects simulated by forskolin but abolished by PKA inhibitors, and YAP knockdown induced expression of galectin-3 and BIM.
Conclusions And Implications: Stimulation of cardiac β-adrenoceptors activated the Mst1/Hippo pathway leading to YAP hyper-phosphorylation with enhanced expression of galectin-3 and BIM. This signalling pathway would have therapeutic potential.
Linked Articles: This article is part of a themed section on Adrenoceptors-New Roles for Old Players. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.14/issuetoc.
Liu Z, Li S, Chen S, Sheng J, Li Z, Lv T iScience. 2024; 27(3):109125.
PMID: 38420594 PMC: 10901089. DOI: 10.1016/j.isci.2024.109125.
Unraveling the role of galectin-3 in cardiac pathology and physiology.
Seropian I, Cassaglia P, Miksztowicz V, Gonzalez G Front Physiol. 2024; 14:1304735.
PMID: 38170009 PMC: 10759241. DOI: 10.3389/fphys.2023.1304735.
Sympatho-adrenergic mechanisms in heart failure: new insights into pathophysiology.
Du X Med Rev (2021). 2023; 1(1):47-77.
PMID: 37724075 PMC: 10388789. DOI: 10.1515/mr-2021-0007.
Zaborska B, Sikora-Frac M, Smarz K, Pilichowska-Paszkiet E, Budaj A, Sitkiewicz D Int J Mol Sci. 2023; 24(17).
PMID: 37685918 PMC: 10488150. DOI: 10.3390/ijms241713111.
Yin Y, Tan M, Han L, Zhang L, Zhang Y, Zhang J Acta Pharm Sin B. 2023; 13(5):1956-1975.
PMID: 37250161 PMC: 10213817. DOI: 10.1016/j.apsb.2023.01.015.